| The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment M Haist, H Stege, S Grabbe, M Bros Cancers 13 (2), 210, 2021 | 234 | 2021 |
| Systemically administered TLR7/8 agonist and antigen-conjugated nanogels govern immune responses against tumors J Stickdorn, L Stein, D Arnold-Schild, J Hahlbrock, C Medina-Montano, ... Acs Nano 16 (3), 4426-4443, 2022 | 63 | 2022 |
| Anticoagulation with factor Xa inhibitors is associated with improved overall response and progression-free survival in patients with metastatic malignant melanoma receiving … M Haist, H Stege, S Pemler, J Heinz, MI Fleischer, C Graf, W Ruf, ... Cancers 13 (20), 5103, 2021 | 45 | 2021 |
| The status of adjuvant and neoadjuvant melanoma therapy, new developments and upcoming challenges H Stege, M Haist, U Nikfarjam, M Schultheis, J Heinz, S Pemler, C Loquai, ... Targeted Oncology 16 (5), 537-552, 2021 | 38 | 2021 |
| Immunomodulatory properties of immune checkpoint inhibitors—more than boosting T-cell responses? M Kuske, M Haist, T Jung, S Grabbe, M Bros Cancers 14 (7), 1710, 2022 | 36 | 2022 |
| T cell-mediated curation and restructuring of tumor tissue coordinates an effective immune response JW Hickey, M Haist, N Horowitz, C Caraccio, Y Tan, AJ Rech, ... Cell reports 42 (12), 2023 | 34 | 2023 |
| Nanodrugs targeting T cells in tumor therapy M Haist, V Mailänder, M Bros Frontiers in Immunology 13, 912594, 2022 | 33 | 2022 |
| Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study HM Stege, M Haist, S Schultheis, MI Fleischer, P Mohr, S Ugurel, ... Cancer Immunology, Immunotherapy 70 (11), 3313-3322, 2021 | 31 | 2021 |
| Immunomodulatory properties of braf and mek inhibitors used for melanoma therapy—Paradoxical erk activation and beyond T Jung, M Haist, M Kuske, S Grabbe, M Bros International Journal of Molecular Sciences 22 (18), 9890, 2021 | 28 | 2021 |
| Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better? M Haist, H Stege, M Kuske, J Bauer, A Klumpp, S Grabbe, M Bros Cancer and Metastasis Reviews 42 (2), 481-505, 2023 | 26 | 2023 |
| Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma—A retrospective multicenter ADOReg study H Stege, M Haist, M Schultheis, MI Fleischer, P Mohr, F Meier, ... Cancers 13 (10), 2312, 2021 | 26 | 2021 |
| Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG M Haist, H Stege, F Rogall, Y Tan, I Von Wasielewski, KC Klespe, F Meier, ... Journal for ImmunoTherapy of Cancer 11 (9), e007630, 2023 | 19 | 2023 |
| Role of hypoxia and the adenosine system in immune evasion and prognosis of patients with brain metastases of melanoma: a multiplex whole slide immunofluorescence study A Mayer, M Haist, C Loquai, S Grabbe, M Rapp, W Roth, P Vaupel, ... Cancers 12 (12), 3753, 2020 | 19 | 2020 |
| The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A … M Haist, H Stege, R Ebner, MI Fleischer, C Loquai, S Grabbe Cancers 14 (9), 2082, 2022 | 15 | 2022 |
| Response to primary chemoradiotherapy of locally advanced oropharyngeal carcinoma is determined by the degree of cytotoxic T cell infiltration within tumor cell aggregates M Haist, J Kaufmann, IM Kur, S Zimmer, S Grabbe, H Schmidberger, ... Frontiers in Immunology 14, 1070203, 2023 | 13 | 2023 |
| Impaired Treg-DC interactions contribute to autoimmunity in leukocyte adhesion deficiency type 1 T Klaus, AS Wilson, E Vicari, E Hadaschik, M Klein, SSC Helbich, ... JCI insight 7 (24), e162580, 2022 | 13 | 2022 |
| SPACEc: a streamlined, interactive Python workflow for multiplexed image processing and analysis Y Tan, TN Kempchen, M Becker, M Haist, D Feyaerts, J Liu, M Toma, ... Nature Communications 16 (1), 10652, 2025 | 12 | 2025 |
| Protease‐and cell type–specific activation of protease‐activated receptor 2 in cutaneous inflammation MI Fleischer, N Röhrig, VK Raker, J Springer, D Becker, S Ritz, M Bros, ... Journal of Thrombosis and Haemostasis 20 (12), 2823-2836, 2022 | 12 | 2022 |
| Neutrophil-specific knockdown of β2 integrins impairs antifungal effector functions and aggravates the course of invasive pulmonal aspergillosis M Haist, F Ries, M Gunzer, M Bednarczyk, E Siegel, M Kuske, S Grabbe, ... Frontiers in immunology 13, 823121, 2022 | 12 | 2022 |
| A Foundation Model for Spatial Proteomics M Shaban, Y Chang, H Qiu, YY Yeo, AH Song, G Jaume, Y Wang, ... arXiv preprint arXiv:2506.03373, 2025 | 11 | 2025 |
Stephan GrabbeProfessor für Dermatologie, Universitaetsmedizin MainzVerified email at unimedizin-mainz.de
